The gastrointestinal side effects plaguing oral semaglutide users may stem from an unexpected source: not the diabetes drug itself, but the chemical enhancer required to make it absorbable. This finding could reshape how pharmaceutical companies approach oral delivery of peptide medications and explain why up to 20% of patients discontinue treatment due to digestive issues.
Rat studies reveal that salcaprozate sodium (SNAC), the absorption enhancer in oral semaglutide formulations, dramatically alters gut microbial communities within three weeks. SNAC depleted two key bacterial families—Muribaculaceae by 62% and Bacteroidaceae by 77%—that normally break down dietary fiber into beneficial short-chain fatty acids. Fecal butyrate levels plummeted 77%, while plasma inflammatory marker TNF-α increased 70% and neuroprotective BDNF dropped 85%. These changes occurred even when SNAC was administered alone, suggesting the enhancer rather than semaglutide drives microbiome disruption.
This research illuminates a critical blind spot in peptide drug development. Most oral biologics require absorption enhancers to survive the digestive tract, yet few studies examine their microbiome effects. The correlation between beneficial bacteria loss and inflammatory markers suggests SNAC may compromise the gut barrier function that these microbes help maintain. While promising for understanding treatment side effects, the findings are preliminary—conducted in healthy rats over just 21 days. Human microbiomes are far more complex, and the clinical relevance remains unclear. Still, this mechanistic insight could guide development of gentler absorption enhancers or targeted probiotic interventions to preserve gut health during oral biologic therapy.
